Status:
COMPLETED
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Lead Sponsor:
Incyte Corporation
Conditions:
MPN (Myeloproliferative Neoplasms)
Eligibility:
All Genders
18+ years
Brief Summary
This is a Phase IV, multicenter, non-interventional, non-randomized, prospective, observational study in an adult population (patients \>18 years old) of men and women who have been diagnosed with cli...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Diagnosis of Polycythemia Vera (PV)
- Willing and able to provide written informed consent
- Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
- Under the supervision of a physician for the current care of PV including but not limited to watchful waiting, acetylsalicylic acid (ASA) 81mg or greater, antithrombotic therapy, Phlebotomy (PHL), Hydroxyurea (HU), interferon (recombinant or pegylated), busulfan, anagrelide
Exclusion
- Participation in an active clinical trial in which the study treatment is blinded
- Life expectancy \<6 months
- Diagnosis of myelofibrosis (MF) \[including primary MF, post-PV MF, or post-essential thrombocythemia MF (post-ET MF)\]
- Diagnosis of secondary Acute Myeloid Leukemia (AML)
- Diagnosis of Myelodysplastic Syndrome (MDS)
- History of or active plan to proceed to allogeneic hematopoietic stem cell transplant in next 3 months
- Splenectomy
Key Trial Info
Start Date :
July 31 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 3 2019
Estimated Enrollment :
2544 Patients enrolled
Trial Details
Trial ID
NCT02252159
Start Date
July 31 2014
End Date
August 3 2019
Last Update
April 26 2021
Active Locations (266)
Enter a location and click search to find clinical trials sorted by distance.
1
Green Valley, Arizona, United States
2
Safford, Arizona, United States
3
Scottsdale, Arizona, United States
4
Tucson, Arizona, United States